Cyprus/Greece/MaltaCyprusGreeceMalta

Athens expands national ban on GM maize varieties

16.05.2007

Athens – Greek Deputy Agriculture Minister Alexandros Kontos has renewed a decree banning the sale of genetically engineered Mon810 Bt maize varieties for another 18 months after an ultimatum of the European Commission ran out in January. In mid-April, his ministry extended this market ban to additional 16 transgenic maize varieties that entered the Common ‘EU Seed Catalogue of Varieties of Agricultural Plant Species’ last year.
Greece fears negative long-term ecological effects such as the development of insect resistance, the disruption of biodiversity among non-harmful and beneficial insects, and a heightened danger of GM cross-pollination due to “the high prevalence of bee-keeping in Greece and the relatively small size of holdings”. The Greek move is based on the so-called safeguard clause, that allows EU member states to implement precautionary measures if they provide scientific evidence for adverse effects on human and animal health or on the environment caused by transgenic crops.
Last summer, the European Food Safety Authority (EFSA) evaluated scientific data presented by the Greek government. However, the EFSA concluded that there was no evidence for any negative impact of the transgenic crops that could justify a national ban on Mon810 acreage. On the basis of this safety assessment, the Commission asked Greece to lift the ban on acreage of the 17 authorized Mon810 varieties.
The Commission is under pressure to push the member states to follow the EU decisions on GM varieties. Otherwise it has to face financial consequences due to market protectionism. In 2006, the World Trade Organisation (WTO) concluded that there was no scientific evidence for a EU GM moratorium from 1998 to 2003 and demanded the Commission lift the existing GM market bans.
The GM-sceptical environmental group Greenpeace applauded Greece’s decision to renew and to extend its ban on the sale and cultivation of genetically-modified maize seeds.

Cyprus/Greece/MaltaCyprusGreeceMalta

19.03.2008

Athens – Greek conglomerate Alapis is further expanding its healthcare arm (production of veterinary pharmaceuticals, medical equipment and nutritional supplements), an area that made up 75% of its total EBITDA of €117.3m in...

Cyprus/Greece/MaltaCyprusGreeceMalta

24.09.2007

Athens – Greek chemical and human and veterinary pharmaceutical company Alapis S.A., which was formed in May by a merger of the Greek firms Veterin, Ebik and Elpharma, is expanding rapidly through acquisitions in south-eastern...

Cyprus/Greece/MaltaCyprusGreeceMalta

11.07.2007

Athens – At the end of May, Greece has launched its official site for the Greek National Contact Point (NCP) for the FP7’s thematic areas “Health“ and “Food, Agriculture and Fisheries, and Biotechnology“ (www.ncp-bionova.gr/)....

Cyprus/Greece/MaltaCyprusGreeceMalta

16.03.2007

Ioannina – Tumor markers are specific to a certain type of cancer and its developmental stage. They are used to estimate a prognosis for the development and treatment of the cancer. Researchers led by John Ioannidis from the...

Politics / Law, Cyprus/Greece/MaltaCyprusGreeceMalta

21.11.2006

Athens – The Greek government and the European Investment Fund (EIF) signed a Memorandum of Understanding in October, which is to implement ‘Jeremie’. The initiative allows the EU Member States and regions to use part of their...

Cyprus/Greece/MaltaCyprusGreeceMalta

12.05.2006

Athens/Napa - Senetek PLC, a US-biopharmaceutical company focused on developing and co-marketing products in the key categories skincare and dermatological worldwide, announced in March that they have signed a cooperative...

Cyprus/Greece/MaltaCyprusGreeceMalta

17.03.2006

Athens/Paris - US-based drug development company Immuno-Designed Molecules (IDM) Inc. signed in February an exclusive licensing and marketing agreement for its cancer drug Junovan (Muramyl Tripeptide Phosphatidylethanolamine) in...

Cyprus/Greece/MaltaCyprusGreeceMalta

17.03.2006

Athens/Brussels - The European Commission has decided that the Greek national ban of MON810 maize is not properly justified and has therefore ordered to lift the ban. Up to now, Greece had referred to the safeguard clause for...

Cyprus/Greece/MaltaCyprusGreeceMalta

29.01.2006

Athens/Nikosia - Drug developer Samaritan Europe has entered into an exclusive distribution agreement with Three Rivers Pharmaceuticals for the marketing and sales of Amphocil® (amphotericin B cholesteryl sulfate complex for...

Cyprus/Greece/MaltaCyprusGreeceMalta

29.01.2006

Crete - Using an implanted device to make the heart beat faster in pacemaker patients with obstructive sleep apnea-hypopnea syndrome does not help, according to a study of Greek researchers. The physicians around Professor Panos...

Displaying results 11 to 20 out of 47

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-cyprus-greece-malta/browse/1/article/athens-expands-national-ban-on-gm-maize-varieties.html

Image Gallery

Stock list

All quotes

TOP

  • PHARMING (NL)0.53 EUR12.8%
  • BAVARIAN NORDIC (D)14.56 EUR10.3%
  • NICOX (F)2.44 EUR7.5%

FLOP

  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • GENFIT (F)22.42 EUR-8.1%
  • DEINOVE (F)12.96 EUR-5.3%

TOP

  • BIOTECH PHARMACON (N)17.50 NOK59.1%
  • WILEX (D)0.92 EUR53.3%
  • E-THERAPEUTICS (UK)28.00 GBP40.0%

FLOP

  • CYTOS (CH)0.17 CHF-93.8%
  • BIONOR PHARMA (N)2.11 NOK-44.9%
  • PROTHENA PLC (IE)28.07 USD-40.8%

TOP

  • SILENCE THERAPEUTICS (UK)256.00 GBP6221.0%
  • IXICO (UK)71.50 GBP810.8%
  • PHARMING (NL)0.53 EUR783.3%

FLOP

  • CYTOS (CH)0.17 CHF-95.8%
  • EVOCUTIS (UK)0.22 GBP-92.5%
  • AGENNIX (D)0.04 EUR-77.8%

No liability assumed, Date: 19.04.2014

Current issue

All issues

Product of the week

Products

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

White Paper